[A20-24] Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2020
Commission awarded on 11.03.2020 by the Federal Joint Committee (G-BA).
Muscles, bones and joints
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.